Correlation Between Protalix Biotherapeutics and Evogene

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Evogene at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Evogene into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protalix Biotherapeutics and Evogene, you can compare the effects of market volatilities on Protalix Biotherapeutics and Evogene and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Evogene. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Evogene.

Diversification Opportunities for Protalix Biotherapeutics and Evogene

-0.83
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Protalix and Evogene is -0.83. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Evogene in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Evogene and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Evogene. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Evogene has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Evogene go up and down completely randomly.

Pair Corralation between Protalix Biotherapeutics and Evogene

Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 0.81 times more return on investment than Evogene. However, Protalix Biotherapeutics is 1.23 times less risky than Evogene. It trades about 0.04 of its potential returns per unit of risk. Evogene is currently generating about -0.03 per unit of risk. If you would invest  117.00  in Protalix Biotherapeutics on August 30, 2024 and sell it today you would earn a total of  52.00  from holding Protalix Biotherapeutics or generate 44.44% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Protalix Biotherapeutics  vs.  Evogene

 Performance 
       Timeline  
Protalix Biotherapeutics 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Evogene 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Evogene has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Protalix Biotherapeutics and Evogene Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protalix Biotherapeutics and Evogene

The main advantage of trading using opposite Protalix Biotherapeutics and Evogene positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Evogene can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will offset losses from the drop in Evogene's long position.
The idea behind Protalix Biotherapeutics and Evogene pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments